Mammography-based artificial intelligence model for predicting axillary lymph node status after neoadjuvant therapy in breast cancer.
Authors
Affiliations (11)
Affiliations (11)
- Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China.
- Department of Nuclear Medicine, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi People's Hospital, Yuxi, China.
- School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
- Shanghai United Imaging Intelligence Co., Ltd., Shanghai, China.
- Department of Radiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Radiology, Baoshan Second People's Hospital, Baoshan, China.
- Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China. [email protected].
- Shanghai United Imaging Intelligence Co., Ltd., Shanghai, China. [email protected].
- School of Biomedical Engineering, ShanghaiTech University, Shanghai, China. [email protected].
- Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [email protected].
- Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China. [email protected].
Abstract
Our objective is to develop a deep learning-based artificial intelligence (AI) model capable of analyzing digital mammography (DM) images to predict axillary lymph node (ALN) status subsequent to neoadjuvant therapy (NAT) in breast cancer patients. We developed and validated an AI model for predicting post-NAT ALN status using images and clinical data of 956 invasive non-specific breast cancer patients with positive ALN metastasis from three medical centers. During development, four image cropping methods and five backbone networks were compared for classification architecture construction. The AI model was evaluated via internal and external test sets, with performance assessed using the ROC curve and AUC. Experiments showed that the AI model using "fixed 5 cm" image clipping and Swin Transformer V2 as the backbone feature extraction network for primary image processing achieved the best ALN status prediction performance. Compared with merely inputting the primary lesion, adding the pre-training model and clinical features further improved the prediction performance of the AI model, in the training set (AUC = 0.823, 95% CI: 0.797-0.846, p < 0.001), internal validation set (AUC = 0.774, 95% CI: 0.722-0.818, p < 0.001), internal test set (AUC = 0.778, 95% CI: 0.739-0.813, p = 0.034) and external test set (AUC = 0.756, 95% CI: 0.700-0.805, p = 0.013). After inputting primary and auxiliary region images and clinical features into the AI model, the AUC value was further improved, reaching above 0.8 in all four datasets. This study constructed an AI model based on baseline DM images that demonstrates good performance in predicting ALN status in breast cancer patients after NAT, providing decision support to avoid excessive surgery. Question Due to the lack of reliable methods to accurately judge the status of ALNs in breast cancer patients after NAT, some patients are overtreated. Findings The AI model we constructed based on the primary lesion of DM before NAT can predict the status of ALNs accurately after NAT. Clinical relevance The AI model can predict the status of ALNs after NAT, which may help clinical selection of more beneficial treatment modalities.